Literature DB >> 22902149

The role of histone demethylases in cancer therapy.

Inga Hoffmann1, Martin Roatsch, Martin L Schmitt, Luca Carlino, Martin Pippel, Wolfgang Sippl, Manfred Jung.   

Abstract

Reversible histone methylation has emerged in the last few years as an important mechanism of epigenetic regulation. Histone methyltransferases and demethylases have been identified as contributing factors in the development of several diseases, especially cancer. Therefore, they have been postulated to be new drug targets with high therapeutic potential. Here, we review histone demethylases with a special focus on their potential role in oncology drug discovery. We present an overview over the different classes of enzymes, their biochemistry, selected data on their role in physiology and already available inhibitors.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902149      PMCID: PMC5528348          DOI: 10.1016/j.molonc.2012.07.004

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  142 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  Histone demethylation by hydroxylation: chemistry in action.

Authors:  Jessica Schneider; Ali Shilatifard
Journal:  ACS Chem Biol       Date:  2006-03-17       Impact factor: 5.100

Review 3.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

4.  Histone modification: cause or cog?

Authors:  Steven Henikoff; Ali Shilatifard
Journal:  Trends Genet       Date:  2011-07-20       Impact factor: 11.639

5.  Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors.

Authors:  Brian Lohse; Anders L Nielsen; Jan B L Kristensen; Charlotte Helgstrand; Paul A C Cloos; Lars Olsen; Michael Gajhede; Rasmus P Clausen; Jesper L Kristensen
Journal:  Angew Chem Int Ed Engl       Date:  2011-08-25       Impact factor: 15.336

6.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.

Authors:  Shohei Hamada; Takayoshi Suzuki; Koshiki Mino; Koichi Koseki; Felix Oehme; Ingo Flamme; Hiroki Ozasa; Yukihiro Itoh; Daisuke Ogasawara; Haruka Komaarashi; Aiko Kato; Hiroki Tsumoto; Hidehiko Nakagawa; Makoto Hasegawa; Ryuzo Sasaki; Tamio Mizukami; Naoki Miyata
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

7.  Yeast Jhd2p is a histone H3 Lys4 trimethyl demethylase.

Authors:  Gaoyang Liang; Robert J Klose; Kathryn E Gardner; Yi Zhang
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

8.  Identification of cell-active lysine specific demethylase 1-selective inhibitors.

Authors:  Rie Ueda; Takayoshi Suzuki; Koshiki Mino; Hiroki Tsumoto; Hidehiko Nakagawa; Makoto Hasegawa; Ryuzo Sasaki; Tamio Mizukami; Naoki Miyata
Journal:  J Am Chem Soc       Date:  2009-12-09       Impact factor: 15.419

9.  Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A.

Authors:  Shinya Mimasu; Toru Sengoku; Seketsu Fukuzawa; Takashi Umehara; Shigeyuki Yokoyama
Journal:  Biochem Biophys Res Commun       Date:  2007-11-26       Impact factor: 3.575

10.  Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex.

Authors:  Riccardo Baron; Claudia Binda; Marcello Tortorici; J Andrew McCammon; Andrea Mattevi
Journal:  Structure       Date:  2011-02-09       Impact factor: 5.006

View more
  40 in total

Review 1.  Histone methylation and aging: lessons learned from model systems.

Authors:  Brenna S McCauley; Weiwei Dang
Journal:  Biochim Biophys Acta       Date:  2014-05-21

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Cancer, epigenetics and the Nobel Prizes.

Authors:  Manel Esteller
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

Review 4.  Selective class IIa HDAC inhibitors: myth or reality.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Claudio Brancolini
Journal:  Cell Mol Life Sci       Date:  2014-09-05       Impact factor: 9.261

Review 5.  The mitochondrial UPR: mechanisms, physiological functions and implications in ageing.

Authors:  Tomer Shpilka; Cole M Haynes
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-22       Impact factor: 94.444

Review 6.  Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.

Authors:  Insa Schiffmann; Gabriele Greve; Manfred Jung; Michael Lübbert
Journal:  Epigenetics       Date:  2016-11-15       Impact factor: 4.528

Review 7.  Cancer's epigenetic drugs: where are they in the cancer medicines?

Authors:  Sorayya Ghasemi
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

8.  Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment.

Authors:  Aditi Qamra; Tsz Wai Chu; Mélanie Criqui; Monika Sharma; Julissa Tsao; Danielle A Henry; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Neil Winegarden; Mathieu Lupien; Lea Harrington
Journal:  Elife       Date:  2020-04-16       Impact factor: 8.140

9.  Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer.

Authors:  Sathiya Pandi Narayanan; Smriti Singh; Amit Gupta; Sandhya Yadav; Shree Ram Singh; Sanjeev Shukla
Journal:  Cancer Lett       Date:  2015-07-28       Impact factor: 8.679

Review 10.  Genomic and Epigenomic Alterations in Cancer.

Authors:  Balabhadrapatruni V S K Chakravarthi; Saroj Nepal; Sooryanarayana Varambally
Journal:  Am J Pathol       Date:  2016-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.